BioCentury
ARTICLE | Clinical News

FDA approves Abilify for bipolar disorder

August 18, 2017 4:27 PM UTC

H. Lundbeck A/S (CSE:LUN) and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said FDA approved an sNDA for once-monthly Abilify Maintena aripiprazole to treat bipolar I disorder. Abilify Maintena is already approved to treat schizophrenia...